Core Viewpoint - Antu Biology's investment dispute with Mobidiag has concluded with a settlement agreement, leading to the dissolution of their joint venture, Antu Mobidiag [1][3]. Group 1: Investment History - In December 2018, Antu Biology signed a joint venture agreement with Mobidiag to establish a company in China, with Antu investing €8 million for a 65% stake and Mobidiag investing €4.3 million for a 35% stake [1]. - Antu Mobidiag was primarily engaged in the research, sales, and after-sales services of molecular diagnostic products [1]. Group 2: Arbitration Process - In April 2024, Antu Biology filed for arbitration with the ICC due to disagreements over the joint venture and licensing agreements, following Mobidiag's unilateral termination of the agreements in November 2021 [2]. - The arbitration case was settled amicably before a hearing, resulting in a settlement agreement where Mobidiag will pay Antu Biology $10 million [3]. Group 3: Financial Performance - Antu Biology reported a revenue of 4.471 billion yuan for 2024, a year-on-year increase of 27.5468 million yuan, representing a growth of 0.62% [3]. - The net profit attributable to the parent company was 1.194 billion yuan, a decrease of 22.987 million yuan, reflecting a decline of 1.89% compared to the previous year [3]. - Antu Mobidiag has been operating at a loss, with net profits of -44.9566 million yuan for 2024 and -3.291 million yuan for the first quarter of 2025 [4]. Group 4: Impact of Dissolution - The dissolution of Antu Mobidiag is in accordance with the settlement agreement and will not materially affect Antu Biology's overall business development or profitability [4].